首页 | 本学科首页   官方微博 | 高级检索  
     

低分子肝素治疗肺源性心脏病急性加重期患者的疗效观察
引用本文:吴正霞,张春峰,王玮,李志强,王宝峰,徐辉. 低分子肝素治疗肺源性心脏病急性加重期患者的疗效观察[J]. 中国卫生产业, 2011, 0(30): 5-6,8
作者姓名:吴正霞  张春峰  王玮  李志强  王宝峰  徐辉
作者单位:宝鸡市中心医院呼吸内科 陕西宝鸡721000
摘    要:目的观察低分子肝素(LMWH)对继发于COPD的肺源性心脏病急性加重期患者肺动脉压(PASP)、血气分析及住院日的影响。方法将152例患者随机分为LMWH治疗组及对照组,2组均给予控制感染、氧疗等常规治疗,治疗组加用LMWH皮下注射10d。检测患者入院及住院11d时PASP、血气分析结果,记录患者达到出院标准时的住院日。结果治疗10d后,治疗组PASP明显降低(u=3.37,P<0.01)、PaO2明显增加(u=2.60,P<0.01),其PaCO2、住院日明显下降,统计学数值分别为(u=2.12,P<0.05)、(u=8.53,P<0.01)。2组结果差异具有统计学意义。结论 LMWH对继发于COPD的肺源性心脏病急性加重期患者可明显改善患者PASP、血气分析,缩短住院日。

关 键 词:慢性阻塞性肺疾病(COPD)  慢性肺源性心脏病  低分子肝素(LMWH)  肺动脉压(PASP)  血气分析  住院日

Therapeutic Effect of LMWH for Acute Exacerbation Patients of Pulmonary Heart Disease
WU Zhengxia,ZHANG Chunfeng,WANG Wei,LI Zhiqiang,WANG Baofeng,XU Hui. Therapeutic Effect of LMWH for Acute Exacerbation Patients of Pulmonary Heart Disease[J]. China Health Industry, 2011, 0(30): 5-6,8
Authors:WU Zhengxia  ZHANG Chunfeng  WANG Wei  LI Zhiqiang  WANG Baofeng  XU Hui
Affiliation:Department Of Respiration,Baoji Central Hospital Shanxi 721008,China
Abstract:Objective To observe the effect of the Low-molecular-weight Heparins Calcium(LMWH)on the pulmonary arterial pressure(PASP)、arterial blood gas analysis and the hospitalization days of the patients,who are diagnosed as the acute stage of chronic pulmonary heart disease secondary to chronic obstructive pulmonary disease(COPD).Methods One hundred and fifty-two patients diagnosed with acute stage of chronic pulmonary heart disease secondary to COPD were randomly divided into two groups,LMWH-treated group and the control group.All the cases were treated with antiinfection,oxygen therapy,bronchodilator,dispelling Phlegm,etc.The LMWH was subcutaneously injected to the LMWH-treated group for 10 days besides the routine treatment.All patients were tested with the PASP、arterial blood gas analysis when they were admitted to hospital within 11 days after hospitalization respectively.And the hospitalization days were recorded that the patients were up to the standard of leaving hospitals.Results Ten days later,The PaO2 of the LMWHtreated group is obviously increased(u=2.60 aP<0.01),and the PASP、PaCO2、hospitalization days is decreased(u=3.37,cP <0.01)、(u=1.99,bP<0.05)、(u =7.53,dP<0.01).There was a statistically significant difference in the two groups with the numerical analysis.Conclusion The Low-molecular-weight Heparins Calcium(LMWH) can remarkably improve the arterial blood gas analysis and decrease the PASP,shorten hospitalization days of the patients who are diagnosed as the acute stage of chronic pulmonary heart disease secondary to chronic obstructive pulmonary disease(COPD).
Keywords:Chronic obstructive pulmonary disease(COPD)  Chronic pulmonary heart disease  Low-molecular-weight Heparins Calcium(LMWH)  Pulmonary arterial pressure(PASP)  Arterial blood gas analysis  Hospitalization days
本文献已被 CNKI 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号